WASHINGTON, D.C.—It is no small task to summarize an entire year’s worth of research accomplishments in any field of medicine, let alone one as complex as rheumatology. At ACR Convergence 2024, the Pediatric Year in Review not only provided a thoughtful summary, but also grouped advances along several different themes. Immune Health & More Jessica…
“What we’re after here is something called active allyship,” said Dr. Dwinita Mosby Tyler, CEO and founder of The Equity Project in her keynote address at ACR Convergence 2024. “It’s where you witness something that might be an injustice or you might see a disparity, and you don’t just talk about it, you research it; you do something about it.”
A third extension of telemedicine flexibilities will continue to allow prescription of controlled substances via telemedicine without an in-person visit through the end of 2025.
According to a new study, fibromyalgia prevalence is elevated in PsA and is associated with elevated disease measures, confounding reliable disease assessment for treat-to-target goals.
The advent of biosimilar medications has offered the promise of significant cost savings for healthcare systems and patients. Biosimilars are highly similar versions of existing biologic drugs, providing a more affordable alternative once the original biologic patent expires. However, the adoption of biosimilars in the U.S. has been hampered by myriad roadblocks, many of which…
WASHINGTON, D.C.—For the first time in U.S. history, older adults are projected to outnumber children by 2034, and their care poses unique challenges to the rheumatologist.1 Normal physiologic changes of aging include but aren’t limited to falling renal function, changes in pharmacokinetics and bone density loss. At the ACR Convergence 2024 Review Course, Namrata Singh,…
WASHINGTON, D.C.—Behçet’s disease (BD) is not a common condition, but we frequently receive referrals to evaluate for it in rheumatology clinics because a patient has oral or genital ulcers. So what’s Behçet’s and what’s not? How can we tell the difference? At the ACR Convergence 2024 Review Course, Johannes Nowatzky, MD, director, New York University…
At a Great Debate session, speakers discussed whether mixed connective tissue disease is a distinct disease entity in rheumatology.
At this ACR Convergence 2024 session, experts discussed new and creative ways to design trials to account for real-world scenarios and to produce information relevant to practicing clinicians.
At the ACR Convergence 2024 Year in Review lecture, experts discussed advancements in disease understanding and treatments, as well as in basic science.